Spektus Pharma and Recipharm Announce Strategic Partnership to Develop and Supply CNS Medicines Using Flexitab™ Oral Drug Delivery Platform
Montreal – Spektus Pharma, an innovator in value added medicine development, and Recipharm, a leading global contract development and manufacturing organization, have entered into a strategic partnership, through Recipharm’s segment responsible for managing its intellectual property. Together, the companies will jointly develop and supply a portfolio of novel Central Nervous System (CNS) focused products. The partnership will leverage Spektus Pharma’s proprietary Flexitab™ oral drug delivery platform to create flexible, breakable extended-release tablets for key global markets, including the USA, Canada, Europe, the UK, and Brazil.
The partnership combines Spektus Pharma’s expertise in formulation development with Recipharm’s extensive manufacturing capabilities, regulatory excellence, and robust global supply chain. Recipharm will play a central role in executing the technology transfer to one of its FDA and EU-approved manufacturing sites, ensuring efficient, high quality production that aligns with global regulatory standards. The two organisations will cooperate to address the growing demand for specialty pharmaceuticals by developing a range of innovative treatments with clinically meaningful benefits and value-added features.
The Flexitab™ Platform:
Flexitab™ is an oral drug delivery technology generating patent-protected extended-release tablets which can be broken into dose-proportional segments, ensuring controlled drug release in both intact and broken forms. Designed specifically for titration-sensitive medications, Flexitab is a cost-effective solution to minimize early treatment side effects by offering personalized dosing and introducing new strengths that help patients manage symptoms at the lowest effective dose.
A Global Partnership Focused on the Depression Segment:
The partnership will initially target the growing antidepressant segment, which has seen a rising prevalence of conditions such as major depressive disorder, anxiety, and other mood disorders. Despite the availability of antidepressant medications, there remains a significant unmet need for treatments that are both more effective and better tolerated by patients.
Spektus Pharma will lead the research and development efforts, combining its knowledge of formulation and clinical development with Recipharm’s global manufacturing, regulatory affairs, and global supply chain management. Together, the two organisations aim to bring together these complementary strengths to design and deliver new formulations that meet the needs of patients worldwide.
“We are excited to join forces with Recipharm to expand the reach of our pipeline and bring our innovative CNS focused products to new partners and patients across global markets,” said Zarvaan Merchant, CEO of Spektus Pharma.
Kieran Chouhan, General Manager of Recipharm’s business segment focused on intellectual property development, said “This partnership exemplifies our ability to combine cutting-edge development platforms like Flexitab™ with Recipharm’s strong manufacturing expertise and regulatory history. Recipharm’s proven track record in executing FDA and EU-approved manufacturing transfers, coupled with our reliable supply chain, makes us the ideal partner to bring these novel CNS therapies to market. By joining forces with Spektus Pharma, we aim to deliver treatments that make a real difference to patients and meet growing global demand for innovative, safe, solutions in CNS care.”
About Spektus Pharma
Spektus Pharma is a Quebec based specialty pharmaceutical company dedicated to developing innovative therapeutics for the treatment of central nervous system disorders. With a pipeline of value-added specialty medicines and a strong focus on patient-centric solutions, Spektus Pharma is committed to advancing treatments for neurological and psychiatric conditions in collaboration with global manufacturing and commercial partners.
For more information on Spektus, please visit www.spektuspharma.com.
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its ReciBioPharm division works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.
Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US and is headquartered in Stockholm, Sweden.
For more information on Recipharm, please visit www.recipharm.com and www.recibiopharm.com
For Media Inquiries:
Recipharm
Guenaelle Holloway, head of communication
Guenaelle.Holloway@Recipharm.com
+44 7730 303 708
Spektus Pharma
info@spektuspharma.com
Recipharm AB
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com
Tags: